Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCapdevila Castillon, Jaume
dc.contributor.authorGómez España, Maria Auxiliadora
dc.contributor.authorGuillot, Mónica
dc.contributor.authorPáez, David
dc.contributor.authorPericay, Carles
dc.contributor.authorSafont, MJ
dc.date.accessioned2022-08-10T06:26:09Z
dc.date.available2022-08-10T06:26:09Z
dc.date.issued2022-04
dc.identifier.citationCapdevila J, Gómez MA, Guillot M, Páez D, Pericay C, Safont MJ, et al. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Clin Transl Oncol. 2022 Apr;24:646–57.
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/11351/7975
dc.descriptionGuideline; Rectal cancer; Total neoadjuvant therapy
dc.description.abstractThe management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. The latest results of international phase III studies have positioned the total neoadjuvant therapy as a potential new standard of care in high risk rectal cancers, however, the best schedule is still not well defined.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical and Translational Oncology;24
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectRecte - Càncer - Tractament
dc.subject.meshRectal Neoplasms
dc.subject.mesh/therapy
dc.subject.meshNeoadjuvant Therapy
dc.titleSEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12094-022-02816-9
dc.subject.decsneoplasias del recto
dc.subject.decs/terapia
dc.subject.decstratamiento neoadyuvante
dc.relation.publishversionhttps://doi.org/10.1007/s12094-022-02816-9
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gómez MA] Department of Medical Oncology, Hospital Universitario Reina Sofía, Córdoba, Spain. IMIBIC, Córdoba, Spain. CIBERONC, Córdoba, Spain. [Guillot M] Department of Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Páez D] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. U705, CIBERER, Barcelona, Spain. [Pericay C] Department of Medical Oncology, Hospital Universitari Mútua de Terrassa, Terrassa, Spain. [Safont MJ] Department of Medical Oncology, Consorcio Hospital General Universitario de Valencia, Universidad de Valencia, Valencia, Spain. CIBERONC, Valencia, Spain
dc.identifier.pmid35303269
dc.identifier.wos000770510800004
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record